vor biopharma inc stock

Grew its holdings in Vor Biopharma by 2994 in the third quarter. The stock opened at 4202 was jumped 1049 in early action.

Vor Biopharma Vorbiopharma Twitter

29 2021 GLOBE NEWSWIRE -- Vor Biopharma Nasdaq.

. Analyst estimates including VOR earnings per share estimates and analyst recommendations. Stay up to date on the latest stock price chart news analysis fundamentals trading and investment tools. Changing the paradigm of cancer thinking.

No significant news for in the past two years. Stock news by MarketWatch. Now owns 2165 shares of the companys stock valued at.

Vor Biopharma Inc complete an upsized 1769 million IPO offering 983 million shares at 18 each. Get the latest Vor Biopharma Inc. Vor Biopharma NYSEVOR - Get Rating had its price objective lowered by stock analysts at Barclays from 5600 to 2600 in a research note issued to investors on Monday Benzinga reportsThe brokerage currently has an overweight rating on the stock.

-036 -419 DATA AS OF Feb 14 2022. Their forecasts range from 2600 to 4600. Get Vor Biopharma Inc VORNASDAQ real-time stock quotes news price and financial information from CNBC.

News Vor Biopharma IncVOR. Engages in developing cell therapies for treating cancer. Change the normal Expose the cancer.

Is estimated to report earnings on 03242022. View real-time stock prices and stock quotes for a full financial overview. VOR Complete Vor Biopharma Inc.

Vor Biopharma Home. The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. VOR a clinical-stage cell and genome engineering company today announced an agreement to develop and manufacture cGMP nucleases.

VOR a clinical-stage cell and genome engineering company today announced that Dr. On average they anticipate Vor Biopharmas stock price to reach 3267 in the next year. The upcoming earnings date is derived from an algorithm based on a companys historical reporting dates.

Robert Ang Vors President and Chief Executive Officer will be participating in a fireside chat at the JMP Securities Hematology and. Common Stock VOR Nasdaq Listed. Find real-time VOR - Vor Biopharma Inc stock quotes company profile news and forecasts from CNN Business.

Find the latest Vor Biopharma Inc. Ad 1000 Strong Buy Stocks that Double the SP. 6 analysts have issued twelve-month price objectives for Vor Biopharmas stock.

Barclayss price target suggests a potential upside of 20952 from the stocks current price. VOR stock quote history news and other vital information to help you with your stock trading and investing. A high-level overview of Vor Biopharma Inc.

Our vendor Zacks. View Vor Biopharma Inc. View daily weekly or.

VOR Stock Trend. VOR detailed stock quotes stock data Real-Time ECN charts stats and more. Vor to Participate in the JMP Securities Hematology and Oncology Summit.

PE Ratio TTM The Price to Earnings PE ratio a key valuation measure is. VOR investment stock information. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies.

Data is currently not available. Given the current short-term trend the stock is expected to fall -3078 during the next 3 months and with a 90 probability hold a price between 372 and 640 at the end of this 3-month period. 1 day agoAkron BioProducts a leading manufacturer of cGMP-compliant technologies for cell and gene therapy and Vor Bio Nasdaq.

102 rows Discover historical prices for VOR stock on Yahoo Finance.

Qxwwibxef C8em

Cambridge Biotech Seeking To Treat Blood Cancers Closes Up 108 Percent In Stock Market Debut The Boston Globe

Markets Cmn Markets January 2022 Crispr Stocks And Market News

Parexel M A Likely To Continue Despite 200m Stock Repurchase Plan

Curious Research Scientist In Lab Coat And Rubber Gloves Looking At Specimen Under Microscope Laboratorio De Analisis Clinicos Dia Del Bioanalista Fibromialgia